Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial,The Lancet Gastroenterology & Hepatology

当前位置： X-MOL 学术 › Gastroenterol. Hepatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
The Lancet Gastroenterology & Hepatology ( IF 30.9 ) Pub Date : 2024-11-07 , DOI: 10.1016/s2468-1253(24)00248-6
A James M Daveson MBBS FRACP, Richard Stubbs MD FRACS, Thomas M Polasek MD PhD, Jorma Isola MD PhD, Robert Anderson PhD FRACP, Jason A Tye-Din PhD FRACP, Mark Schoeman PhD FRACP, Claudette Lionnet MBChB DA SA, Swee Lin Chen Yi Mei PhD FRACP, Jelena Mihajlović PhD, Martina Wirth PhD, Evelyn Peelen PhD, Amelie Schreieck PhD, Hella Kohlhof PhD, Daniel Vitt PhD, Andreas Muehler MD, Franziska Buriánek MD

IMU-856 is an orally available and systemically acting small molecule modulator of sirtuin 6 (SIRT6), a protein that serves as a transcriptional regulator of bowel epithelium regeneration. We aimed to evaluate the safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856 in healthy participants and in patients with coeliac disease.

中文翻译：

SIRT6 调节剂 IMU-856 在乳糜泻中的安全性、临床活性、药效学和药代动力学：一项首次人体、随机、双盲、安慰剂对照的 1 期试验

IMU-856 是一种口服且具有全身作用的 sirtuin 6 （SIRT6）小分子调节剂，SIRT6 是一种用作肠上皮再生转录调节因子的蛋白质。我们旨在评估 IMU-856 在健康参与者和乳糜泻患者中的安全性、临床活性、药效学和药代动力学。

更新日期：2024-11-07

点击分享查看原文

点击收藏

阅读更多本刊新发论文